TMCI senior director charged with insider trading in U.S.
David Pidgeon, a senior director at Treace Medical Concepts, Inc. (TMCI), has been indicted for securities fraud based on insider trading. He allegedly used confidential information about TMCI's poor financial performance in October 2025 to purchase short-term put options before the company publicly announced a significant net loss and reduced revenue projections, leading to a stock price drop. Pidgeon faces a maximum of 45 years in prison across two securities fraud charges.
Did You Lose Money on Treace Medical Concepts, Inc. (TMCI)? Levi
Levi & Korsinsky LLP has filed a class action securities lawsuit against Treace Medical Concepts, Inc. (NASDAQ:TMCI) on behalf of investors who suffered losses due to alleged securities fraud between May 8, 2023, and May 7, 2024. The lawsuit claims that the company made false statements and concealed that competition negatively impacted demand for its "Lapiplasty" product, leading to revenue decline and necessitating alternative product development. Investors who lost money are urged to act before June 10, 2025, to learn about their rights to seek recovery.
522,900 Shares in Treace Medical Concepts, Inc. $TMCI Purchased by Renaissance Technologies LLC
Renaissance Technologies LLC acquired 522,900 shares of Treace Medical Concepts, Inc. ($TMCI) in the first quarter, valued at approximately $701,000, giving them a 0.81% stake. Other institutional investors also adjusted their holdings, with hedge funds and institutions collectively owning 84.08% of the company. Despite cautious analyst sentiment and a "Reduce" average rating, the company surpassed Q1 earnings expectations, reporting revenue of $45.38 million and a loss of $0.24 per share.
Armistice Capital (TMCI) discloses 6.36M-share Treace Medical ownership stake
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership stake of 6,364,000 shares in Treace Medical Concepts, Inc. (TMCI), representing 9.79% of the outstanding common stock. This ownership is held directly by Armistice Capital Master Fund Ltd., with Armistice Capital serving as its investment manager, granting them shared voting and dispositive power over the shares. The filing specifies key figures such as the total shares beneficially owned, the percentage of the class, and the shared voting and dispositive powers.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50
Treace Medical Concepts (NASDAQ:TMCI) recently released its second-quarter report, showing revenues of US$45 million, beating expectations. Analysts have moderately uplifted their sentiment, upgrading loss per share forecasts and raising the consensus price target by 18% to US$5.50. Despite this, revenue growth is expected to slow significantly compared to historical performance and industry peers.
Treace Medical Concepts (TMCI) officer disposes shares for tax or exercise costs
Sean F. Scanlan, Chief Innovation Officer at Treace Medical Concepts (TMCI), reported a Form 4 transaction indicating the disposition of 9,814 shares of common stock. These shares were delivered or withheld to cover exercise price or tax liability. Following this transaction, Scanlan directly holds 679,863 shares, which includes restricted stock units and accounts for a transfer of shares to a former spouse.
Treace Medical Concepts (TMCI) CEO John T. Treace reports 19.2% beneficial stake
John T. Treace, CEO of Treace Medical Concepts, has filed an amended Schedule 13G indicating a 19.2% beneficial ownership stake in the company, totaling 12,530,959 shares. This ownership includes direct holdings, shares in family trusts, his spouse's holdings, and stock options exercisable within 60 days. The filing, based on 64,976,624 outstanding shares as of June 30, 2026, details both sole and shared voting and dispositive powers over these shares.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50
Treace Medical Concepts (NASDAQ:TMCI) recently released its Q2 earnings, with revenues exceeding expectations at US$45m and statutory losses coming in smaller than anticipated at US$0.24 per share. Following the report, analysts increased their price target for TMCI to US$5.50, reflecting a moderate uplift in sentiment despite expectations for slower revenue growth compared to the historical average and industry peers. The analysts reconfirmed loss per share estimates for next year, indicating improving intrinsic value for the business.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50
Treace Medical Concepts, Inc. (NASDAQ:TMCI) recently released its second-quarter report, showing revenues of US$45m, surpassing estimates by 3.3%, and statutory losses that were less than expected at US$0.24 per share. Following the report, analysts increased their consensus price target for TMCI by 18% to US$5.50, and slightly upgraded loss per share forecasts for the year. However, the company's revenue growth is projected to slow to 2.1% annually until the end of 2026, which is significantly lower than its historical 18% p.a. growth and slower than other industry participants.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Given Consensus Rating of "Reduce" by Analysts
Analysts have issued a consensus "Reduce" rating for Treace Medical Concepts, Inc. (NASDAQ:TMCI), with an average 12-month price target of $5.17, despite the company beating recent quarterly revenue and EPS estimates. The stock opened at $4.67, and significant insider and institutional ownership is noted. Insiders have recently purchased a substantial amount of shares.
Treace Medical Concepts (NASDAQ:TMCI) Price Target Raised to $5.00 at Truist Financial
Truist Financial has increased its price target for Treace Medical Concepts (NASDAQ:TMCI) from $4.00 to $5.00, while maintaining a "hold" rating, suggesting a potential upside of 10.13%. Despite this, the broader analyst consensus remains "Reduce" with a target of $5.17. The company recently reported a narrower-than-expected loss and exceeded revenue estimates, with notable insider buying and significant institutional ownership.
Truist Securities Adjusts PT on Treace Medical Concepts to $5 From $4, Keeps Hold Rating
Truist Securities has raised its price target for Treace Medical Concepts (TMCI) from $4 to $5, while maintaining a "Hold" rating on the stock. This adjustment comes after Treace Medical Concepts recently increased its earnings guidance for the full-year 2026. The medical technology company specializes in surgical solutions for bunion and midfoot deformities.
Treace Medical Concepts (TMCI) Stock Jumps As Cash Burn Eases But Sales Stall
Treace Medical Concepts (TMCI) saw its stock jump 8.7% despite essentially flat Q2 revenue of US$45.4m and a net loss of US$15.9m. Investors reacted positively to a smaller adjusted EBITDA loss and reduced cash burn, indicating a market preference for financial discipline over top-line growth. While bulls see potential in a broader foot and ankle platform, bears are concerned about mix pressures from lower-priced procedures impacting revenue and margins.
Treace Medical Concepts, Inc. (TMCI) Stock Price, News, Quote & History
This page provides a comprehensive overview of Treace Medical Concepts, Inc. (TMCI) stock, including its current price, after-hours trading, historical data, and key financial metrics. It also features company news, analyst ratings, and a detailed description of its medical devices and technologies, such as the Lapiplasty System and Nanoplasty 3D Minimally Invasive Bunion Correction System. The article outlines the company's performance overview, earnings trends, and comparative analysis with other medical device companies.
Treace Medical Concepts: Q2 Earnings Snapshot
Treace Medical Concepts Inc. (TMCI) reported a second-quarter loss of $15.9 million, equating to 24 cents per share. The orthopedic medical device maker generated $45.4 million in revenue for the period and expects full-year revenue to be between $204 million and $212 million. This financial report was generated using data from Zacks Investment Research.
Treace Medical Concepts (NASDAQ:TMCI) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS
Treace Medical Concepts (NASDAQ:TMCI) announced its quarterly earnings, reporting an adjusted loss of $0.24 per share, surpassing the consensus estimate of a $0.30 loss, with revenues of $45.38 million beating the $44.02 million forecast. The company raised its 2026 revenue guidance to $204 million–$212 million and improved its full-year adjusted EBITDA guidance to a loss of $3 million–$5 million. Despite a 4% year-over-year revenue decline due to a shift towards lower-priced minimally invasive products, TMCI's stock traded up 8.7% following the announcement.
Treace Medical Concepts earnings beat by $0.06, revenue topped estimates
Treace Medical Concepts (NASDAQ: TMCI) reported a second-quarter EPS of $-0.24, surpassing the analyst estimate of $-0.30 by $0.06. The company's revenue for the quarter reached $45.4 million, exceeding the consensus estimate of $43.94 million. Despite a 117.91% increase in its stock price over the last three months, the stock is down 28.55% in the last 12 months, and its financial health is rated as "good performance" by InvestingPro.
Treace Medical Concepts Releases Q2 2026 Financial Results
Treace Medical Concepts, Inc. (TMCI) reported a narrower Q2 2026 loss per share of -$0.24, beating the -$0.30 estimate by 20.0%. The company's revenue for the quarter was $45.4 million, representing a 4.0% year-over-year decrease. Management projects full-year revenue to be between $204.0 million and $212.0 million.
Press Release: Treace Medical Concepts Reports Second Quarter 2026 Financial Results
This press release details Treace Medical Concepts' financial results for the second quarter of 2026. It will likely cover key financial metrics such as revenue, net income, and earnings per share, as well as provide an outlook for future performance. The report will offer insights into the company's operational achievements and challenges during the period.
Treace Medical Concepts Inc (TMCI) (Q2 2026) Earnings Call Highlights: Revenue Declines 4% but ...
Treace Medical Concepts Inc (TMCI) reported a 4% revenue decline to $45.4 million in Q2 2026, though adjusted EBITDA loss narrowed and cash usage significantly decreased. The company is experiencing increased adoption of new bunion systems and expects improved performance in the latter half of 2026, driven by new product launches and seasonal strength. Full-year 2026 revenue guidance was raised, despite anticipated continued revenue declines through Q3 due to product mix shifts.
Treace Medical Concepts, Inc. (TMCI) Stock Analysis: Navigating Challenges with Innovative Medical Solutions
Treace Medical Concepts (TMCI) is a healthcare company innovating in bunion and foot deformity correction with products like the Lapiplasty System. Despite financial challenges including negative revenue growth and ROE, the company's unique product offerings present potential for investors. Its stock shows volatility, and analyst sentiment is mixed, highlighting the balance between its pioneering medical solutions and current financial performance.
About 40% of Treace’s Lapiplasty surgeon users use new systems
Treace Medical Concepts reported a 4% decline in Q2 2026 revenue to $45.4 million year-over-year, alongside a net loss of $15.9 million. Despite the revenue dip, the company saw an 8% reduction in operating expenses and significantly decreased year-to-date cash usage by 57%. Treace also raised its full-year 2026 revenue guidance and improved its adjusted EBITDA loss outlook, noting increased adoption of its newer bunion systems among Lapiplasty surgeons.
Securities Lawsuit Alert: Treace Medical Concepts, Inc. (TMCI) Investors - Contact Levi & Korsinsky Before June 10, 2025
Levi & Korsinsky LLP has filed a class action securities lawsuit against Treace Medical Concepts, Inc. (NASDAQ:TMCI). The lawsuit alleges that the company made false statements and concealed information regarding competition and demand for its Lapiplasty product, leading to revenue decline. Investors who suffered losses between May 8, 2023, and May 7, 2024, are encouraged to contact the firm before June 10, 2025, to learn about potential recovery.
Join Class Action to Recover Losses from Treace Medical Concepts
Levi & Korsinsky LLP has filed a class action securities lawsuit against Treace Medical Concepts, Inc. (TMCI) for alleged securities fraud between May 8, 2023, and May 7, 2024. The lawsuit claims that the company made false statements regarding competition impacting demand for its primary product, the Lapiplasty, leading to declining revenue. Shareholders who suffered losses during this period are encouraged to contact Levi & Korsinsky before June 10, 2025, to learn about their rights to seek recovery.
Treace Medical Concepts (TMCI) Expected to Post Earnings on Friday
Treace Medical Concepts (TMCI) is projected to release its Q2 2026 earnings before market open on Friday, August 7th, with analysts anticipating a loss of $0.30 per share and revenue of $44.02 million. Despite exceeding estimates in the previous quarter, the company remains unprofitable. Insider buying and institutional ownership are noted, while analyst sentiment generally recommends "Reduce" for the stock.
Treace Medical Concepts Number of Employees 2026 | Employee Count & Headcount Data
Treace Medical Concepts, Inc. (TMCI) has approximately 444 total employees worldwide as of March 2026, a 2.3% decline from 2023. The company is actively hiring with 28 job postings in 2026, though this represents a 48.6% decline from 2025. Its workforce is concentrated in the United States, and the largest functional group is Engineering.
BlackRock (TMCI holder) files amended 13G showing 959,320 Treace Medical shares
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 959,320 shares in Treace Medical Concepts, Inc., which represents 1.5% of the outstanding common stock. This filing indicates that BlackRock holds sole voting and dispositive power over these shares. While various underlying persons may have rights to dividends or sale proceeds, no single person possesses an interest exceeding five percent of Treace's outstanding common shares through these holdings.
Treace Medical Concepts Inc (TMCI) Institutional Confidence
The article provides an analysis of the institutional confidence score for Treace Medical Concepts Inc (TMCI), which currently stands at 5.00, ranking 107 out of 199 in its industry. Institutional shareholding proportion decreased by 4.20% quarter-over-quarter to 58.61%. James Simons is highlighted as the largest institutional shareholder, and a table details significant changes in holdings by other institutional investors.
TMCI|Treace Medical Concepts Inc|Price:4.030|Chg%:+0.020
This article provides a comprehensive stock analysis of Treace Medical Concepts Inc (TMCI) from TradingKey. It highlights the company's strong fundamentals and high growth potential, despite an average market performance in the last month. The analysis rates its valuation as "fairly valued" within the Healthcare Equipment & Supplies industry and notes high institutional ownership.
Treace Medical Concepts Inc (TMCI) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Treace Medical Concepts Inc (TMCI) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. The page also presents current stock performance data, including its market capitalization, recent price, and daily change.
Investors in Treace Medical Concepts, Inc. (TMCI): Protect Your Rights - Contact Levi & Korsinsky Before June 10, 2025
Levi & Korsinsky, LLP has announced a class action securities lawsuit against Treace Medical Concepts, Inc. (TMCI) for alleged securities fraud between May 8, 2023, and May 7, 2024. The lawsuit claims that the company made false statements and concealed that competition affected demand for its Lapiplasty product, leading to revenue decline and necessitating an alternative product. Investors suffering losses are encouraged to contact Levi & Korsinsky for more information about their rights before June 10, 2025.
Treace Medical Concepts Inc (TMCI) Cash Flow
This article provides a detailed quarterly and annual cash flow statement for Treace Medical Concepts Inc (TMCI), covering operating, investing, and financing activities from FY2020Q1 to FY2026Q1. It breaks down various cash flow components such as net income, changes in working capital, capital expenditures, and debt issuance/repayment. The content also includes an FAQ section explaining key cash flow concepts and providing specific figures for TMCI.
Treace Medical Concepts Inc Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article provides a revenue breakdown for Treace Medical Concepts Inc (TMCI), noting that relevant data for business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly presents the current stock price, market capitalization, and states that there is no P/E TTM available.
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Treace Medical Concepts, Inc. (TMCI) breached their fiduciary duties to shareholders. Long-term shareholders are encouraged to contact the firm to discuss potential corporate governance reforms, recovery of funds, or other legal relief. The firm emphasizes that shareholder involvement can enhance company transparency and value.
TradingKey
This article provides an income statement analysis for Treace Medical Concepts Inc (TMCI), detailing quarterly and annual financial performance metrics such as revenue, operating expenses, operating profit, and net income. It also includes FAQs explaining how to interpret the income statement, key metrics for stock analysis, and recent financial figures for the company. The data shows significant fluctuations in revenue and consistent net losses across most reported periods.
Treace Medical Concepts, Inc. Revenue Breakdown – NASDAQ:TMCI
Treace Medical Concepts, Inc. (NASDAQ: TMCI) generated $212.69 million USD in revenue last year, primarily from its Medical Devices segment. This segment was also the top performer in the previous year, contributing $209.36 million USD. The vast majority of the company's revenue, $212.69 million USD last year, came from the United States.
Investors urged to act as law firm probes Treace Medical's board for possible breaches of duty.
Halper Sadeh LLC is investigating whether Treace Medical Concepts, Inc. officers and directors breached their fiduciary duties. The law firm is offering free consultations for long-term Treace stockholders who may seek reforms, financial awards, or other remedies. Shareholders are encouraged to act quickly due to potential time limits on claims, as the investigation aims to improve corporate governance and protect investor interests.
Treace Medical Concepts schedules Q2 earnings release and conference call
Treace Medical Concepts (NASDAQ: TMCI) will announce its Q2 2026 financial results before the market open on August 7, 2026. Following the release, company management will host an earnings conference call at 8:00 a.m. ET on the same day to discuss the results. Interested parties can access the call via registration or a webcast available on the company's investor relations website.
Treace Medical Concepts to Release Q2 2026 Financial Results
Treace Medical Concepts (TMCI) is scheduled to release its Q2 2026 financial results before trading on August 7, 2026, followed by a conference call at 8:00 am ET. The company is highlighting its significant market potential, targeting 1.1 million surgical candidates among 67 million Americans affected by bunions, and its technological leadership with products like the Lapiplasty® 3D Bunion Correction System. Analyst ratings show a mixed view, with Truist maintaining a "Hold" and Lake Street having a "Buy" rating.
Treace will discuss Q2 results live before markets open Aug. 7
Treace Medical Concepts (NasdaqGS: TMCI) will announce its second-quarter 2026 financial results before market open on Friday, August 7, 2026. The company will host a conference call at 8:00 a.m. ET, which will also be accessible via a live webcast on its investor relations website. This announcement highlights recent insider net buying and notes that the upcoming results will be crucial for assessing financial performance, guidance, and execution.
Treace to Report Second Quarter 2026 Financial Results on August 7, 2026
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) announced it will release its second quarter 2026 financial results before market open on Friday, August 7, 2026. The company will host a conference call at 8:00 am ET to discuss these results. Interested investors can register for the call or access a live and archived webcast on the company's investor relations website.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Consensus Recommendation of "Reduce" from Brokerages
Treace Medical Concepts (NASDAQ: TMCI) has received a "Reduce" consensus rating from seven brokerages, with an average 12-month price target of $4.97. Despite analysts' cautious outlook, the company exceeded recent quarterly earnings and revenue estimates. Notably, insider and institutional buying has been strong, with the CEO purchasing shares and hedge funds owning a significant portion of the stock.
Treace Medical Concepts Price Target Raised to $4.00/Share From $2.00 by Truist Securities
Truist Securities has raised its price target for Treace Medical Concepts (NASDAQ: TMCI) shares to $4.00, up from the previous target of $2.00. This adjustment follows the firm's re-evaluation of the medical device company's financial outlook. While the price target has increased, Truist Securities has maintained a Hold rating on the stock.
Treace Medical Concepts (NASDAQ:TMCI) Given New $4.00 Price Target at Truist Financial
Truist Financial has increased its price target for Treace Medical Concepts (NASDAQ:TMCI) to $4.00, up from $2.00, while maintaining a "hold" rating, suggesting an 11.6% potential downside. The company recently reported better-than-expected quarterly results with an EPS of -$0.28 and revenue of $47.2 million, leading to a 2.8% rise in its stock price. Insider trading shows CEO John T. Treace acquired 61,750 shares, and institutional investors collectively own 84.08% of the company's stock.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Short Interest Down 46.6% in June
Treace Medical Concepts, Inc. (NASDAQ:TMCI) experienced a significant 46.6% decline in short interest in June, bringing the total to 1.75 million shares or about 3.5% of its outstanding shares. Despite weak fundamentals, including a negative net margin and anticipated full-year loss, insider buying has been notable, with CEO John T. Treace acquiring additional shares and institutional investors adjusting their positions. Analysts currently hold a consensus "Reduce" rating for the stock with a price target of $4.77.
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Treace Medical Concepts, Inc. (TMCI)
Johnson Fistel, PLLP is investigating potential breaches of fiduciary duty by officers and directors of Treace Medical Concepts, Inc. (TMCI) on behalf of long-term shareholders who held shares continuously since before May 8, 2023. The investigation focuses on alleged false and misleading statements regarding competition impacting the demand for Treace's primary product, the Lapiplasty, and the company's need to accelerate alternative product offerings. Shareholders may have standing to seek corporate governance reforms and the return of funds to the company.
Law firm investigates Treace Medical for alleged false statements affecting shareholders.
Johnson Fistel, PLLP is investigating Treace Medical Concepts, Inc. on behalf of long-term shareholders for alleged breaches of fiduciary duty by its officers and directors. The investigation stems from allegations that Treace made false or misleading statements regarding its business, specifically concerning competition and revenue declines for its main product. Shareholders who held shares before May 8, 2023, may be eligible for corporate governance reforms and financial recovery.
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Treace Medical Concepts, Inc. (TMCI)
Johnson Fistel, PLLP is investigating potential breach of fiduciary duty claims against officers and directors of Treace Medical Concepts, Inc. (TMCI) on behalf of long-term shareholders who held shares continuously before May 8, 2023. The investigation stems from allegations in a previously filed securities class action that claimed the company made materially false or misleading statements regarding competition and declining revenue impacting its primary product. Shareholders could seek corporate governance reforms and financial returns to the company.
Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System
Treace Medical Concepts, Inc. successfully completed the first surgical case using its new HyperPlate™ XM Dynamic Compression Locking Implant System. This system, designed for midfoot and hindfoot fusions, combines locking screws and dynamic compression for enhanced stability and is complemented by specialized sterile instruments for efficient procedures. The launch is part of Treace's strategy to expand its market presence and product portfolio in foot and ankle surgery.
TMCI LAWSUIT ALERT: Levi & Korsinsky Notifies Treace Medical Concepts, Inc. Investors – Lead Plaintiff Deadline June 10, 2025
Levi & Korsinsky LLP has announced a class action securities lawsuit against Treace Medical Concepts, Inc. (NASDAQ: TMCI) for alleged securities fraud between May 8, 2023, and May 7, 2024. The lawsuit claims that the company made false statements and/or concealed that competition impacted demand for its "Lapiplasty" product, leading to revenue decline and the need for alternative products. Investors who suffered losses during this period are encouraged to learn about their rights to seek recovery, with a lead plaintiff deadline of June 10, 2025.
